Last week, an FDA advisory committee voted to recommend that six popular peptides be added to the list of substances compounding pharmacies are allowed to use. The six are BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. A seventh, emideltide (also called DSIP), was voted down.
The votes were close, and they went against the recommendation of the FDA's own scientific staff. They also do not change the law on their own. Here is what happened and what comes next.
Some background
Compounding pharmacies that operate under section 503A of the Food, Drug, and Cosmetic Act can only make drugs from approved bulk ingredients. A peptide that is not part of an FDA-approved drug and has no official monograph needs to be on the FDA's 503A bulks list before pharmacies can use it [4]. None of these seven peptides are on that list.
In 2023 the FDA placed a group of popular peptides in Category 2, its bucket for bulk substances that may pose significant safety risks. That effectively shut them out of pharmacy compounding [3]. In April 2026 the agency announced it would remove 12 peptides from Category 2 and scheduled advisory committee meetings to consider adding some of them to the bulks list [1][2]. Leaving Category 2 did not make any of them legal to compound. We covered the earlier rounds of this fight in The FDA reclassified 14 peptides: what it means and RFK Jr. announces FDA peptide policy changes.
What FDA staff said before the meeting
On June 29 the FDA posted its briefing documents for the Pharmacy Compounding Advisory Committee. For each of the seven peptides, agency scientists concluded that the evidence did not support adding it to the bulks list [3]. The documents pointed to thin human data, unknown long-term safety and a possible risk of immunogenicity, meaning an unwanted immune reaction to the peptide or its impurities [4].
A few specifics from the briefing materials, as reported by CNN [4]:
- BPC-157 was first described in the medical literature in 1993. FDA noted limited information on long-term safety and effectiveness.
- TB-500 appears to have been first synthesized from thymosin beta-4 in 2003. FDA wrote that it "may pose a significant risk for immunogenicity."
- MOTS-c was discovered in 2015. FDA found animal data on obesity and insulin sensitivity but "no clinical studies to assess the safety and effectiveness" in humans.
- Epitalon raised a theoretical cancer concern, because long-term upregulation of telomerase could in principle push cells toward uncontrolled growth.
How the committee voted
The committee met on July 23 and 24 and reviewed each peptide for specific proposed uses [4]:
| Peptide | Use discussed | Vote to add to bulks list |
|---|---|---|
| BPC-157 | Ulcerative colitis | 8 yes, 6 no, 1 abstain |
| TB-500 | Wound healing | 8 yes, 6 no, 1 abstain |
| KPV | Wound healing and inflammatory conditions | 8 yes, 6 no, 1 abstain |
| MOTS-c | Obesity and osteoporosis | 7 yes, 5 no, 2 abstain |
| Semax | Neurological conditions including migraine | 8 yes, 5 no, 1 abstain |
| Epitalon | Insomnia | 7 yes, 4 no, 1 abstain |
| Emideltide | Opioid withdrawal and insomnia | 6 yes, 7 no, 1 abstain |
Emideltide was the only one rejected [5].
Members who voted yes mostly argued about where people get these peptides today. Many users buy them online from overseas suppliers labeled "for research use," with no prescription and no quality oversight. "That's where the real danger lives, and that's where the enforcement belongs," committee member Dr. Hal Mohammed said during the meeting [4].
Members who voted no focused on the evidence. Dr. Elizabeth Rebello of the University of Texas MD Anderson Cancer Center said she was "concerned that we're responding to a market-induced demand" and wanted the decision to rest on solid science [4].
The panel's makeup drew attention too. NPR reported before the meeting that several members had ties to the peptide industry, including some who work for companies that offer injectable peptides [3].
What the vote changes
Advisory committee votes are recommendations. Pharmacies still cannot legally compound any of these six peptides, and they remain in limbo until the FDA takes further action [4].
To change their status, the FDA would need to add the peptides to the bulks list through formal notice-and-comment rulemaking. That usually means a proposed rule, a public comment period and a final rule, and it can take more than a year [4].
There is a faster option on the table. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, told CNN he thinks it is "possible, maybe even likely" that the agency announces a period of enforcement discretion, letting pharmacies compound the peptides while rulemaking plays out [4]. Health Secretary Robert F. Kennedy Jr. has spoken publicly in favor of wider peptide access, which makes a quicker path more plausible.
NPR reported that the committee is expected to reconvene to look at additional peptides at a later meeting [3].
What this means if you follow these peptides
For now, nothing has changed at the pharmacy counter. A prescription for compounded BPC-157 or TB-500 from a 503A pharmacy is still outside federal law until the FDA acts.
If the FDA does move forward, expect conditions. The committee reviewed each peptide for a specific use and dosage form, and any final rule or interim policy could limit routes of administration, salt forms or sourcing. Research-use-only vendors would not be covered by a change to pharmacy compounding rules either way.
We will update our peptide pages as the FDA responds. In the meantime, you can compare research on each one on the BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon pages.
Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice. Regulatory situations change quickly. Check current FDA guidance and talk with a qualified healthcare provider before making treatment decisions.
Sources
- Orrick. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances List. April 2026.
- US FDA to convene expert panel to review wider access to some peptides. Reuters. April 15, 2026.
- Stone W. FDA scientists flag concerns with peptides as RFK Jr. tries to ease access. NPR. June 30, 2026.
- Howard J. FDA advisers support easing restrictions on six peptides. Here's what those drugs are and what happens next. CNN. July 31, 2026.
- FDA Advisers Back Looser Rules For Six Peptides, Reject One. Bloomberg Law. July 2026.
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.